Preeclampsia is a pregnancy complication which manifests as newonset hypertension, proteinuria, and a spectrum of other symptoms. While the underlying causes are still a subject of much debate, it is commonly believed that placental ischemia is a central cause. The ischemic placenta secretes factors which are believed to be responsible for the maternal syndrome; most notably the anti-angiogenic protein soluble fms-like tyrosine kinase 1 (sFlt-1). We have reported that induction of the carbon monoxide (CO) producing protein heme oxygenase-1 restored angiogenic imbalance and reduced blood pressure in a rat model of placental ischemia, and that CO blocks hypoxia-induced sFlt-1 production from placental tissue in vitro. We therefore hypothesized that direct administration of CO by a CO-releasing molecule (CORM) would blunt the placental ischemia-induced increase in sFlt-1 and thus the hypertension characteristic of this model.
Preeclampsia is one of the most common complications of pregnancy, affecting ~5-7% of all pregnancies. The classical hallmarks of the disorder include new-onset hypertension, proteinuria, and edema; however, it is now recognized that a broader spectrum of symptoms are adequate as secondary indicators in addition to hypertension. 1 Though the underlying cause of the disorder remains unclear, a common finding is failure to adequately remodel the maternal vasculature which supplies the developing fetoplacental unit with adequate blood flow, leading to chronic hypoxia and ischemia. 2 In response, the placenta can secrete factors into the maternal circulation which are responsible for the symptomatic phase of the disease, including prominently the anti-angiogenic protein soluble fms-like tyrosine kinase 1 (sFlt-1). 3, 4 sFlt-1 is a splice variant of the longer vascular endothelial growth factor (VEGF) receptor Flt-1, but lacks the transmembrane and intracellular signaling domains of the longer protein, causing the extracellular recognition domain to be secreted. While soluble, sFlt-1 acts as a decoy receptor for VEGF and acts as an antagonist for the protein. 5 In addition to studies which have found elevated sFlt-1 in the plasma of patients suffering preeclampsia, numerous groups have found that exogenous sFlt-1 causes endothelial dysfunction and hypertension. 4, 6, 7 Likewise, among the most common complications in patients taking the anti-VEGF monoclonal antibody bevacizumab for cancer therapy are hypertension and proteinuria. 8 It would be useful then to investigate the utility of reducing sFlt-1 levels in repeated preeclampsia patients to control the endothelial dysfunction which is a hallmark of the disease.
One potential approach that has been suggested is increased production of endogenous carbon monoxide (CO). Produced endogenously by the enzyme heme oxygenase (HO) enzymes, CO is an often under-appreciated signaling molecule, acting as both a potent vasodilator, as well as acting on angiogenic pathways. 9, 10 For instance,
Carbon Monoxide Releasing Molecules Blunt Placental Ischemia-Induced Hypertension
Jozkowicz et al. found that CO could up-regulate production of VEGF in endothelial cells, as well as stimulate proliferation and migration. 9 Later, Cudmore et al. reported that CO-releasing molecules (CORMs) inhibited production of sFlt-1 in response to various stimuli in cultured cells. 11 We have previously reported that induction of HO attenuated the hypertension and other negative cardiovascular effects of placental ischemia, 12 sFlt-1 excess, 7 and tumor necrosis factor-α excess 13 in vivo. We have also shown that CORMs blunted hypoxia-induced sFlt-1 release from placental tissue in vitro. 14 Given these data, we hypothesized that administration of CO by CORMs would blunt placental ischemiainduced hypertension by reducing placental production of sFlt-1 in vivo. To test this hypothesis, we utilized a wellestablished rodent model of placental ischemia, the Reduced Uterine Perfusion Pressure (RUPP) model, and daily IV administration of a CORM.
MATERIALS AND METHODS

Animals
Timed pregnant Sprague Dawley rats (Harlan, Indianapolis, IN) were received on gestational day 11, held at a constant 23 °C, and were put on a 12:12-hour light-dark cycle with food and water ad libitum. All protocols were approved by the University of Mississippi Medical Center Institutional Animal Care and Use Committee and followed the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals.
RUPP procedure and CO donor administration
On gestational day 14, RUPP-treated animals were subjected to aortic and bilateral ovarian artery constriction as previously described. 15 Briefly, animals were anesthetized by controlled 3% isoflurane (Webster), and a midline abdominal incision was made. After externalization of both uterine horns, one single 0.203 mm silver surgical clip was placed on the abdominal aorta above the iliac bifurcation. One 0.100 mm silver surgical clip was placed on both the left and right ovarian arteries which supply the uterus to prevent compensatory flow. Rats absorbing all pups as a result of the procedure were excluded from the study. During the same procedure, animals were instrumented with chronic jugular catheters which were exteriorized at the nape of the neck. Animals in the CO donor groups were administered CORM-3 (5 mg/kg in phosphate-buffered saline) once daily from gestational day 14-19, while animals in the control groups were given equal volumes of CORM-3 which was formulated 24 hours ahead of time to allow for CO to be fully devolved (i-CORM).
Tricarbonylchloro(glycinato)ruthenium(II) ([Ru(CO) 3 Cl(glycinate)] or CORM-3, MW = 295 g/mol) was synthesized from ([Ru(CO) 3 Cl 2 ] 2 ) as described previously. 16 
Measurement of arterial pressure
On gestational day 18, animals were anesthetized as above, and implanted with indwelling carotid catheters. The catheter was externalized at the nape of the neck subcutaneously.
The following day, animals were placed in restraint cages and acclimatized for 1 hour. Mean pressure was determined over the course of 30 minutes via direct pressure transducers (ADI instruments).
Tissue harvest
Rats were anesthetized as above. The uterus was externalized, through a ventral midline incision, and blood was collected by cannulation of the abdominal aorta for isolation of plasma and serum. Records were made of the viable and reabsorbed pups present in each animal, and individual pups and placentas were weighed and recorded. Representative placental samples (2 randomly selected from each horn), the thoracic aorta, and the liver were flash frozen in liquid nitrogen and stored at −80 °C for later analysis.
Measurement of sFlt-1, VEGF, and tumor necrosis factor-α
Placental protein was prepared from a representative placenta from individual rats. Briefly, the frozen tissue was mechanically ground by mortar and pestle in liquid nitrogen. Tissue fragments were resuspended in radioimmunoassay buffer with protease inhibitor cocktail, PMSF, and sodium orthovanadate (Santa Cruz Biotechnology). Homogenization was performed via automated tissue processor (MP Bio) and the solution was cleared by centrifugation at 12,000 g for 20 minutes. Resulting protein concentration was measured by the bicinchoninic acid method (Pierce Biotechnology). VEGF and sFlt-1 were both measured by sandwich ELISA (R&D systems) in duplicate according to manufacturer's protocols.
Measurement of glomerular filtration rate
In a separate cohort of animals, subjects were treated as indicated above for their respective treatment group, except they did not receive carotid catheters on GD 18. On gestational day 19, 1 hour after receiving a final dose of CORM-3, glomerular filtration rate (GFR) was measured by transcutaneous measurement of FITC-Sinistrin clearance. Specifically, under light anesthesia (isoflurane, 1.5%) 7.5 mg/100 g body weight FITC-Sinistrin bolus was administered by jugular catheter and a NIC-Kidney (Mannheim Pharma, Germany) transcutaneous fluorescence detector was attached to a depilated area on the animal's back. Sinistrin clearance was monitored for 2 hours, and GFR determined by MPD Lab (Mannheim Pharma) fitted to a one compartment model as previously described. 17 
Statistical analysis
All figures display mean data ± SE. Comparisons between groups were performed by 1-way analysis of variance with Tukey's multiple comparisons test at a significance threshold value of P < 0.05. All statistical comparisons and graphs were generated with Prism 6 (Graphpad).
RESULTS
Blood pressure and fetal outcomes
The RUPP procedure was performed on gestational day 14, and jugular catheters were implanted for administration of the CO donor CORM-3 or i-CORM. From GD 14-18, freshly prepared CORM-3 or vehicle was administered daily i.v. After carotid catheterization on GD 18, blood pressure was assessed by direct measurement on GD19, and fetal outcomes and weights determined. Blood pressure was significantly increased in response to the RUPP procedure when compared to controls (107 ± 1 vs. 137 ± 3 mm Hg, P < 0.05). Administration of CORM-3 significantly decreased blood pressure in both control (97 ± 3 mm Hg) and RUPP (113 ± 1 mm Hg) animals when compared to their respective controls (Figure 1 ). Fetal weights were significantly decreased in RUPP animals vs. controls (2.2 ± 0.1 vs. 1.9 ± 0.1 g, P < 0.05). There was no significant effect of CORM-3 on either sham (2.1 ± 0.1 g) or RUPP (1.7 ± 0.1) fetuses (Figure 2a 
Effect of CORM on placental angiogenic imbalance
As the effects of placental angiogenic imbalance on blood pressure have been previously described in this model, 12, 18 we wished to determine whether the changes in blood pressure observed were due to shifts in the proangiogenic protein VEGF or the anti-angiogenic protein sFlt-1. In response to the RUPP procedure, placental sFlt-1 levels ( Figure 3a) were increased significantly over their sham-operated counterparts (596 ± 45 vs. 1,004 ± 81 pg/mg, P < 0.05). Surprisingly, in both sham (1,143 ± 122 pg/mg) and RUPP (1,213 ± 73 pg/mg) animals, placental sFlt-1 was significantly increased when compared to their respective controls (Figure 3a) . Also surprisingly, while we found an expected increase in placental VEGF in RUPP animals compared to sham treated (23 ± 2 vs. 31 ± 2 pg/mg, P < 0.05), we also observed differential effects on placental VEGF in response to CORM. While there was no significant effect of CORM on placental VEGF in sham animals (25 ± 3 pg/mg), there was a significant reduction in placental VEGF in RUPP animals treated with CORM-3 (Figure 3b) . Likewise, when we measured free plasma VEGF, we again found a reduction in circulating free VEGF in RUPP animals compared to controls (527 ± 30 vs. 363 ± 44 pg/ml, P < 0.05). Again counter to our expectations, we found that CORM-3 treatment led to significant reductions in free circulating VEGF in both sham (294 ± 9 pg/ml) and RUPP (256 ± 23 pg/ml) animals (Figure 3c ). Together, these data suggest that CORM-3 treatment did not reverse the angiogenic imbalance in RUPP, but in fact shifted the sFlt-1/VEGF ratio to a more anti-angiogenic state.
Effects of CORM-3 on glomerular filtration rate
As it appeared that the CO donor had no beneficial effect on angiogenic imbalance in the RUPP animal, we then wished to determine whether it could be having a direct effect on renal function. To that end, we determined GFR in animals on GD19 with RUPP and/or CORM-3 administration. In response to RUPP treatment, we observed a strong trend of reduced GFR, (1.1 ± 0.1 vs. 0.85 ± 0.1 ml/min/100 g b.w., P = 0.1) when compared to control animals. While we observed no significant effect of CORM-3 on GFR in shamoperated animals, we saw a significant increase in GFR in RUPP animals receiving CORM-3 (1.5 ± 0.1 ml/min/100 g b.w.) (Figure 4) . Together, these data suggest that CORM-3 is selectively affecting renal function, possibly through vasodilation of the renal arteries and subsequent effects on GFR.
DISCUSSION
One of the great challenges in obstetrical practice is the management of preeclampsia, with little in the way of In response to RUPP treatment, there was a significant increase in placental levels of sFlt-1 (a), with a less pronounced nonsignificant increase in placental VEGF (b). Administration of CORM-3 significantly increased placental sFlt-1 in sham animals while having no effect in the RUPP group. No significant effect of CORM-3 was noted in either experimental group. RUPP treatment caused a significant decrease in the circulating levels of free bio-available VEGF (c), as did administration of CORM-3. CORM-3 had no effect on circulating free VEGF in RUPP animals. Abbreviations: CORM, carbon monoxide releasing molecule; RUPP, Reduced Uterine Perfusion Pressure model; sFlt-1, soluble fms-like tyrosine kinase 1; VEGF, vascular endothelial growth factor. effective treatment options. Current guidelines call for magnesium sulfate administration for seizure prophylaxis, administration of antihypertensives to mitigate maternal hypertension, and bed rest. None of these options, however, halts the progression of the disease or remits the widespread maternal endothelial dysfunction which is prevalent in the symptomatic phase of the disorder. Indeed, in severe preeclampsia, the therapeutic goal is simply to prolong gestation as long as possible to allow for fetal development before induction of labor, delivery of the placenta, and ultimate remittance of the maternal symptoms. 1, 19 At the same time, it is rapidly becoming clear that preeclampsia is closely tied to increased lifelong cardiovascular risk in both the mother and the baby. 20, 21 Coupled with the acute contribution to fetal and maternal morbidity and mortality, it is clear that there is a significant need for new therapeutic approaches to manage this common obstetrical disorder.
One potential system which has been suggested as a potential therapeutic for the management of preeclampsia is the HO system. 22, 23 This was due to HO's ameliorative effect on inflammatory pathways known to be key in preeclampsia. Subsequent studies linking HO induction with suppression of sFlt-1 in response to inflammatory and hypoxic stimuli, further strengthening the potential for this pathway. 11, 14 These data, and others showing that HO induction has antihypertensive effects in a variety of experimental models, [24] [25] [26] led us to perform a series of experiments demonstrating that HO induction could attenuate hypertension associated not only with placental ischemia, but individually with exogenous sFlt-1 and tumor necrosis factor-α administration during late-term gestation. 7, 12, 13 In the first of these studies, we demonstrated that HO induction by cobalt protoporphyrin could not only attenuate the hypertension associated with each placental ischemia, but could help restore angiogenic balance, attenuate placental oxidative stress, and reduce production of vascular endothelin-1; suggesting improved vascular endothelial function. 12 Subsequently, using an established sFlt-1 infusion model, we found that HO-1 induction attenuated both the hypertension and vascular endothelin-1 overproduction, which are a direct result of elevated circulating sFlt-1 levels. 7 Finally, we found that HO-1 induction could partially block the systemic effects of chronically elevated tumor necrosis factor-α, one of the inflammatory cytokines most closely associated with placental ischemia and preeclampsia. 13 Interestingly, there are indications in the literature that the ability of HO to suppress sFlt-1 production could be derived from its production of CO. 11, 14 The Ahmed lab group previously reported that CO could block production of sFlt-1 in response to exogenous VEGF in endothelial cells. 11 We previously demonstrated that in rat placental tissue, both HO-1 induction and direct administration of a CO donor were able to prevent release of sFlt-1 in response to a hypoxia challenge similar to that seen in preeclamptic placentas. 14 Given this, in the present study, we tested the hypothesis that chronic administration of a CO donor molecule would attenuate placental ischemia-induced hypertension by suppressing hypoxia-driven sFlt-1 release from the placenta. Consistent with our hypothesis, we saw that administration of CO by a CORM significantly blunted placental ischemiainduced hypertension in our rodent model without any noted teratogenicity or decrease in fetal and placental mass, while also causing a modest decrease in blood pressure in the sham control group. However, contrary to our proposed mechanism, we found that CORM administration significantly increased placental levels of sFlt-1 in control animals, with no effect on RUPP-treated animals. Likewise, the RUPP-induced increased placental VEGF was attenuated by administration of CORM. This shift in proangiogenic and anti-angiogenic protein production by the placenta was reflected in the maternal circulation, as CORM administration decreased free plasma VEGF to levels similar to those seen in RUPP animals with no effect on RUPP animals directly. Together, these data demonstrate that CORM administration does not normalize placental ischemia-induced angiogenic imbalance in vivo. It is also interesting to note that in contrast to our previous work looking at the effect of CO on sFlt-1 secretion ex vivo, we found that CORM administration did not suppress sFlt-1 production from the placenta. One possible explanation comes from recent work demonstrating that sFlt-1 release from the placenta may not be regulated by changes in sFlt-1 production per se, but by solubilization of sFlt-1 that is normally retained in the ECM of the placenta. 27 It is possible that the CO administration, potentially through increased blood flow, normalized this mechanism and caused more sFlt-1 to be retained in the placental ECM.
While our original hypothesis was shown to be incorrect, the RUPP-induced increase in blood pressure was significantly decreased by CORM. In order to examine the mechanisms which were decreasing blood pressure in response to CO, we looked at measurements of renal function. The rational for doing so relied on previously published data suggesting that the hypertension associated with placental ischemia is at least in part due to decreased GFR, potentially through decreased renal plasma flow. 15, 28 Given the known role of CO as a potent vasodilator, we then hypothesized that CORM administration could be acting directly on the renal vasculature to increase blood flow and thus GFR. To that end, we investigated the effects of RUPP treatment and CORM administration on glomerular filtration rate in vivo. Similar to previously published data, RUPP-treated animals exhibited a trend to decreased GFR, though this did not quite meet statistical significance. While having no effect on control animals, we did note a significant increase (~50%) in maternal GFR 1 hour post CORM administration. Though not definitive, it is at least suggestive that CORM is acting directly on the renal vasculature to vasodilate and increase perfusion ultimately resulting in increased GFR and lowered blood pressure. This is consistent with work published by Ryan et al., who found that CO donor molecules could increase renal blood flow ~30% through soluble guanylyl cyclase dependent mechanisms. 29 Whether the vasodilation was restricted to the renal vasculature or affected peripheral vasodilation is not clear from these experiments. What has been shown is that placental ischemia is associated with decreased NO bioavailability in the kidney with associated decreases in renal plasma flow, and it is possible that the vasodilatory actions of CORM in this instance are more pronounced in the renal vasculature than in the periphery, as to whether the peripheral vasculature is similarly constricted is unclear. 15 Here, we have demonstrated that administration of a CO donor molecule attenuates placental ischemia-induced hypertension through mechanisms independent of sFlt-1 and VEGF. Further, despite decreased blood pressure (and presumably perfusion), we found no effect on fetal body weight or mortality. Our current hypothesis is that CO is acting directly on the maternal kidney to attenuate the renal effects of placental ischemia on renal hemodynamics. Further detailed mechanistic studies on the renal hemodynamic, and possibly tubular, effects of CORM administration should prove enlightening. Likewise, the effects of exogenously delivered CO on the production and activity of endogenous nitric oxide in the placenta and vasculature could be of continuing interest.
